Hope for a Lassa fever vaccine as scientists reveal jab shows promise

Researchers from Philadelphia University and Thomas Jefferson University tested a new vaccine on mice and guinea pigs and said it showed 'good protection' and was a step forward.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Lassa fever is a major threat in Western Africa. The large number of people living at risk for this disease calls for the development of a vaccine against Lassa virus (LASV). We generated live-attenuated LASV vaccines based on measles virus and Mopeia virus platforms and expressing different LASV antigens, with the aim to develop a vaccine able to protect after a single shot. We compared the efficacy of these vaccines against LASV in cynomolgus monkeys. The vaccines were well tolerated and protected the animals from LASV infection and disease after a single immunization but with varying efficacy. Analysis of the immune res...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
Crooke Dolores Gavier-Widén After the re-introduction of African swine fever virus (ASFV) genotype II isolates into Georgia in 2007, the disease spread from Eastern to Western Europe and then jumped first up to Mongolian borders and later into China in August 2018, spreading out of control and reaching different countries of Southeast Asia in 2019. From the initial incursion, along with domestic pigs, wild boar displayed a high susceptibility to ASFV and disease development. The disease established self-sustaining cycles within the wild boar population, a key fact that helped its spread and that pointed to th...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
The envelope glycoproteins GP1 and GP2 of Lassa virus (LASV) bind to the host cell receptor(s) to mediate viral infection. So far, no approved vaccines or specific treatment options against LASV exist. To develop specific fusion inhibitors against LASV, we solved the crystal structure of the post-fusion 6 helix bundle (6-HB) formed by two heptad repeat domains (HR1 and HR2) of GP2. This fusion core contains a parallel trimeric coiled-coil of three HR1 helices, around which three HR2 helices are entwined in an antiparallel manner. Various hydrophobic and charged interactions form between HR1 and HR2 domains to stabilize the...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Publication date: 8 August 2019Source: Cell, Volume 178, Issue 4Author(s): Kathryn M. Hastie, Robert W. Cross, Stephanie S. Harkins, Michelle A. Zandonatti, Anatoliy P. Koval, Megan L. Heinrich, Megan M. Rowland, James E. Robinson, Thomas W. Geisbert, Robert F. Garry, Luis M. Branco, Erica Ollmann SaphireSummaryLassa virus (LASV) causes hemorrhagic fever and is endemic in West Africa. Protective antibody responses primarily target the LASV surface glycoprotein (GPC), and GPC-B competition group antibodies often show potent neutralizing activity in humans. However, which features confer potent and broadly neutralizing antib...
Source: Cell - Category: Cytology Source Type: research
Discussion Dengue is an important arboviral infection that affects about 40% of the world population. It is found mainly in topical and subtropical areas of the world mainly in developing countries but it range is spreading including the United States. A review of common arboviruses can be found here. It is a flaviavirus with 4 distinct serotypes named DENV-1 through DENV-4 and is spread by A. aegypti a day biting mosquito. Infection with one serotype confers immunity to that serotype but not the others. It does offer some protection for cross-infection but this only lasts a few months. Incubation period is 3-14 days with ...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
by Brien K. Haun, Varney Kamara, Abigail S. Dweh, Kianalei Garalde-Machida, Saymajunkon S. E. Forkay, Melissa Takaaze, Madhuri Namekar, Teri Ann S. Wong, Ayesha E. R. Bell-Gam Woto, Peter Humphreys, Ophelia I. Weeks, Mosoka P. Fallah, John M. Berestecky, Vivek R. Nerurkar, Axel T. Lehrer Filoviruses such as Ebola virus (EBOV) cause outbreaks of viral hemorrhagic fevers for which no FDA-approved vaccines or drugs are available. The 2014–2016 EBOV outbreak in West Africa infected approximately 30,000 people, killing more than 11,000 and affecting thousands more in areas still suff ering from the effects of civil wars....
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Publication date: Available online 11 July 2019Source: Antiviral ResearchAuthor(s): Yu-Jin Kim, Beatrice Cubitt, Emily Chen, Mitchell V. Hull, Arnab K. Chatterjee, Yingyun Cai, Jens H. Kuhn, Juan C. de la TorreAbstractSeveral mammarenaviruses, chiefly Lassa virus (LASV) in Western Africa and Junín virus (JUNV) in the Argentine Pampas, cause severe disease in humans and pose important public health problems in their endemic regions. Moreover, mounting evidence indicates that the worldwide-distributed mammarenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen of clinical significance. The l...
Source: Antiviral Therapy - Category: Virology Source Type: research
Abstract Several mammarenaviruses, chiefly Lassa virus (LASV) in Western Africa and Junín virus (JUNV) in the Argentine Pampas, cause severe disease in humans and pose important public health problems in their endemic regions. Moreover, mounting evidence indicates that the worldwide-distributed mammarenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen of clinical significance. The lack of licensed mammarenavirus vaccines and partial efficacy of current anti-mammarenavirus therapy limited to an off-label use of the nucleoside analog ribavirin underscore an unmet need for novel th...
Source: Antiviral Research - Category: Virology Authors: Tags: Antiviral Res Source Type: research
In 2019, a small outbreak of Bolivian hemorrhagic fever was reported at a hospital in La Paz, Bolivia.  The following background data on Bolivian hemorrhagic fever are abstracted from Gideon www.GideonOnline.com and the Gideon e-book series. [1,2]  Primary references are available from the author. Bolivian hemorrhagic fever (BHF) is caused by Machupo virus (Arenaviridae, Tacaribe complex, Mammarenavirus).  The disease was initially described in 1959 as a sporadic hemorrhagic illness in rural areas of Beni department, eastern Bolivia; and the virus itself was first identified in 1963.  BHF is most common...
Source: GIDEON blog - Category: Databases & Libraries Authors: Tags: Ebooks Epidemiology Outbreaks ProMED Source Type: blogs
Contributors : Sylvain Baize ; Natalia PietrosemoliSeries Type : Expression profiling by high throughput sequencingOrganism : Macaca fascicularisLassa fever is a major threat in Western Africa. The large number of people living at risk for this disease calls for the development of a vaccine against Lassa virus (LASV). We compared the efficacy of measles-based and Mopeia-based vaccine platforms against LASV in cynomolgus monkeys. The vaccines were well tolerated and protected the animals from Lassa virus infection and disease after a single immunization but with different efficacy. Analyses of immune responses demonstrated ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Macaca fascicularis Source Type: research
More News: Guinea Health | Health | Lassa Fever | Vaccines